

Index

a

- A-1155463 42, 274, 277, 280
- A-1331852 275, 280
- Ab-6 214, 215
- ABBV-467 277, 284, 291, 292
- aberrant protein–protein interactions (aPPIs) 163–194
- A β -oligomerization modulation 213–216
- ABT-737 270, 275, 276
- acceptor photobleaching 62–63
- activity-based protein profiling (ABPP) 90
- adenomatous polyposis coli (APC) 230, 300, 373–384
- aducanumab 122
- affinity purification coupled with mass spectrometry (AP-MS) 76–81
- Akt/GSK-3 β NFATc1 252
- alanine 2, 280, 301
- alanine scanning mutagenesis 309
- all-hydrocarbon stapling approach 42, 228–230, 245, 246, 251
- allosteric regulators 344
- AlphaFold (AF) 39, 40, 141, 142, 144, 145, 147, 153, 154, 393, 395
- AlphaFold2 141, 144, 148–150, 256, 393, 395
- Alzheimer's disease 11, 88, 122, 164, 173–174, 213, 343, 344, 398
 - A β 189–191
- AMG-176 42, 286, 293–294
- AMG-397 287, 293–294
- amyloid-beta (A β) 11, 122, 139, 189, 191, 215–216, 343
- amyloidosis 213–216
- anagrelide 355–356
- androgen receptor (AR) 254, 256
- angle of incidence 115
- ankyrin repeat sequences (ANK) 318
- anti-amyloid-beta antibodies 122
- anti-apoptotic proteins 264–300
- antibodies 121–123, 401
- antibody–drug conjugates (ADCs) 121–122
- anti-diabetes stapled peptides 253
- antigen–antibody interactions 3–4
- anti-inflammation stapled peptides 253
- antitumor stapled peptides 245–251
- anti-viral
 - HIV fusion inhibitor 210–212
 - pan-coronavirus fusion inhibitor 212–213
- antiviral stapled peptides 251–252
- anti-viral vaccines and antibodies 122–123
- APC-binding region (ABR) 374–376
- APC–Asef interaction 375–377, 379, 381, 383
- more sensitive FP method 382–383
- peptides
 - computer-aided design of tripeptide inhibitors 381

APC–Asef interaction (*contd.*)

MAI-150-derived peptidomimetic
inhibitors 377

MAI-203 377–379

MAI-400 379–380

MAI-516 380–381

minimal Asef sequence 376

small molecule inhibitors 381–382

structural insights into 375–376

apoptosis 6, 17, 41–45, 139, 172, 209,
220, 228, 229, 235, 246, 249, 263,
264, 266–268, 278, 279, 281, 291,
292, 307, 318, 319, 322, 343, 344,
356, 357, 381

aqueous formaldehyde 225

armadillo repeat 1 (R1) 301

armadillo repeat domain (ARM)
373–377, 381

atomic desolvation effects 143

atomic pair potentials 143

auxin 347, 350

AZD0466 273, 279

AZD4320 273, 279

AZD5991 42, 277, 288, 294, 299

azide-alkyne cycloaddition 62, 223

b

B cell antigen recognition and
activation 9

B-cell CLL/lymphoma 3 (BCL-3)
inhibitors 320

biological functions 318–320

structural characteristics 318

B-cell CLL-lymphoma 10 (BCL-10)
inhibitors 320–322

biological functions 320–321

cancer 322

structural characteristics 321–322

B-cell lymphoma-2 (BCL-2) 10, 17, 18,
40–42, 228–229, 236, 245, 249, 250,
264–300, 357

protein 264–300

anti-apoptotic proteins 267

binding sites 266–267

B-cell lymphoma 9 (BCL9) 206–208,
230, 263, 288–290, 295–296,
300–307

physiological functions 300

B-cell receptor (BCR) 9, 309, 321

Bcl-2 homology domain 3 (BH3) 18, 41,
42, 165, 229, 249, 264–268, 275,
276, 278–281, 290–294, 396, 397

BCL6-corepressor (BCoR) 316

BCL-6 small molecule inhibitors
310–318

BCL6-targeted diseases 309

biological functions 307–308

structural characteristics 308–309

Bcl-xL 18, 40–42, 52, 165, 229, 250,
264–281, 283–286, 288, 290, 292

β -catenin 206, 208, 229–230, 249, 251,
295, 300–307, 363, 373, 374

β -catenin binding region 373, 374

β -catenin/B-cell lymphoma 206–208

β -catenin/BCL9 inhibitor 295, 301, 304,
306, 307

β -catenin/TCF interaction 229–230

17- β -estradiol (E2) 9, 10, 357, 361, 362

β -hairpin cyclic peptides 253–254

BH3 mimetics 41, 267, 268, 280

BI3812 310–315

binding constant (K_d) 67, 116, 301

binding site information 143

BioID 82–84

bioinformatics analysis 118

bioisosteric replacement 293, 303

biological general repository for
interaction datasets (BioGRID)
391, 392

biotechnology, fostering innovations in
17–18

biotin-tagged protein 307

BM-903 278

Bok protein 266

BRD9500 355, 356

bromodomains (BDs) 130

c

CA-170 47, 52, 346

CAPRI experiments 151–153

- capsid assembly inhibitor (CAI) 231
 CASP14-CAPRI experiment 152–153
 CASP15-CAPRI experiment 153
 caspase-9 17, 357
 caspase recruitment domain (CARD) 321
 CASP-CAPRI experiment 152
 C—H activation 224, 225
 c-IAP1 44–45
 c-Jun N-terminal kinase (JNK) pathway 373
 C-terminal basic domain (B-domain) 300
 CCT369347 314, 317–318
 CCT372064 317–318
 CD40-CD40L 45–46
 cell-penetrating peptide (CPP) 231, 236, 377, 380
 cell permeability 179, 180, 207–209, 219, 221, 226, 232, 236, 306
 cell proliferation 16, 47, 48, 172, 230, 263, 300, 305, 318, 319, 322, 351, 355, 358, 359, 364, 381
 cell-surface PPIs 118–119
 cellular imaging 64
 cellular signal transduction 5–6, 357
 cereblon (CRBN) 131, 290, 349–350, 360
 CETSA 91, 379, 382
 chaperone–client interactions 4
 chemical cross-linking mass spectrometry 352
 chemical inducers of proximity (CIPs) 347, 348
 chemokine receptors 3
 chemoproteomics 84, 362
 chromatography purification 166, 174
 clustering-based on maximal cliques (CMC) 392, 394
 ClusterONE 89
 Co-crystal complex analysis 291
 Co-crystallization 310
 co-fractionation coupled with mass spectrometry (CF-MS) 88–90
 co-immunoprecipitation (CO-IP) 76, 116, 307, 377
 colorectal cancer (CRC) 49, 73, 230, 248, 267, 300, 303, 305–307, 319, 322, 353, 373–375, 377, 379, 381, 383
 computer-aided drug design (CADD) 131, 316
 Coronaviruses 231
 Coulomb interaction 145
 cross-linking mass spectrometry (XL-MS) 77, 84–88, 95–96
 Cryo-EM 140
 crystallographic analysis 279, 349
 Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) 62, 223
 CYC065 46–47, 52
 cyclin-dependent kinase (CDK) 46–47, 51, 52, 163, 351, 354, 369
 cyclin K degraders 351–354
 cyclosporin A (CypA) 255, 357–359, 361, 363–364
 Cys–Cys stapling approach 224
- d**
 data analysis, FRET 63
 database of interacting proteins (DIP) 391, 392, 394
 data-independent acquisition (DIA) 81, 95, 363
 death domain (DD) 321
 deep learning 14, 15, 39, 75, 140–142, 144–148, 154–155, 256, 394
 diabetes therapeutics 216
 diazepam 293
 diene linkers 224
 differentiation 6, 8, 9, 66, 87, 90, 124, 229, 252, 300, 307, 318, 381
 Diffuse2Direct 391, 392
 dimerization 63, 106, 308, 360, 363
 directed evolution strategy 82
 disease mechanisms 10–11, 70, 153, 243
 dithiocarbamate chemistry 248
 DLA-Ranker 146
 DNA-binding domain (DBD) 172, 254
 DNMDP 355–356
 docking algorithm 38, 140–144, 147, 148, 152
 double-stapling technique 252

- driving target-based drug discovery 17
- drug design 29, 35, 36, 39, 45, 95, 96, 117, 121, 125, 131, 267, 276, 280, 281, 294, 309, 320
- drug discovery 1, 16, 17, 29–30, 34–38, 40, 51, 53, 63–65, 76, 81, 117, 121, 164, 219–221, 225–227, 236, 237, 263, 323, 376, 383, 389, 395, 401–402
- PPI 52, 344, 402
- SPR-guided screening and optimization in 120–123
- stapled peptides in 220–221
- drug screening methods 64, 120, 132, 268, 361, 383
- dynamic light scattering (DLS) 166, 355
- e**
- electron microscopy 12, 69, 166, 355
- electrostatic interactions 30, 143, 145, 191, 215, 266
- end-binding protein 1 (EB1) 373, 374
- end-to-end structure prediction 141, 148–151
- enzymatic activities, PPI 29, 32, 51
- enzyme-substrate interactions 3
- epidermal growth factor receptor (EGFR) 16–17, 49, 108, 128, 391, 400
- epitope competition experiments 126–128
- EQUIDOCK 144
- f**
- familial adenomatous polyposis (FAP) 373, 374
- fast Fourier translation (FFT) 142–144
- FK506 357, 359
- fluorescein isothiocyanate (FITC) 172, 173, 207, 209, 382
- fluorescence activated cell sorting (FACS) 82, 83, 120
- fluorescence lifetime imaging (FLIM) 62, 67, 69, 71
- fluorescence polarization (FP) 13, 165, 212, 213, 302, 303, 310, 362, 363, 376
- fluorescence polarization-based high-throughput screening 268
- 3-(4-fluorophenyl)-*N*-phenylbenzamide derivatives 305–307
- foldamer 44, 164, 165, 181–183, 185, 186, 188, 189, 191, 194, 205, 212, 214–216
- foldameric peptidomimetics 205
- Förster resonance energy transfer (FRET) advantages and limitations 67–68
- cellular imaging 64
- clinical diagnosis 65–66
- conformational changes 64
- drug discovery 64–65
- environmental and agricultural sciences 66–67
- materials science 66
- mechanism of 61–63
- molecular interactions 63
- structural biology 66
- FOXO1 83–84
- fragment-based drug discovery (FBDD) 37–38, 51, 323
- fragment-based lead discovery (FBLD) 37
- fragment-based screening 30, 291, 292
- Frexalimab 45
- FRNC-1 252
- FWJ-D4 291
- FWJ-D5 291, 399, 400
- g**
- galectin-3 (Gal-3) 128
- γ -AApeptides 181, 205–216
- gantenerumab 122
- Gaussian function 143
- GDC-0917 44, 52, 346
- gene enrichment analysis 310
- gene expression 3, 6, 7, 18, 19, 29, 33, 105, 115, 209, 300, 304, 306, 317
- regulation of 6–8

- generative unconstrained intelligent drug engineering (GUIDE) 393, 401
- genomic distance-based pairing 149
- geometric vector perceptron-graph neural network (GVP-GNN) 147
- glial cell line-derived neurotrophic factor (GDNF) 119
- glutamate/aspartate 222–223
- G protein-coupled receptors (GPCRs) 3, 6, 82
- GQN-B37-E 283, 291
- graph neural networks (GNNs) 147
- green fluorescent protein and mCherry (GFP/mCherry) 62
- GSK137 305, 314, 316–317
- guanine nucleotide exchange factor (GEF) activity 373, 374
- h**
- heat shock protein (HSP) 4
- heat shock protein 90 (Hsp90) 48
- α -helical structures 221, 236
- α -helix cyclic peptides 244–253
- Helios 360
- hemoglobin 31
- heparanase 129
- heparin (Hep) 128–129
- hepatocyte growth factor (HGF) 374
- HIF-1 α PPI's inhibitor 209–210
- high mobility group protein-1 (HMGB1) 129
- high-throughput screening (HTS) 35–37, 51, 63, 65, 70, 71, 132, 268, 279, 281, 293, 310, 316, 352, 353, 363, 364
- HIV-1 capsid proteins 252
- HIV fusion inhibitor 210–212
- homeostasis 9, 10, 19, 164, 169, 235, 266
- Hook effect 347, 348
- HQ005 352, 354
- human protein reference database (HPRD) 391, 392
- Huntingtin yeast interacting protein E-like kinase (HYPK) 123–124
- hybridization chain reaction (HCR) 107, 108, 110, 210
- hydrocarbon peptide stapling 245, 248, 253, 254
- hydrocarbon-stapling strategy 42
- hydrogen peroxide 82, 107
- hydrophobic interactions 2, 30, 31, 143, 165, 191, 266, 278, 301, 309, 316, 321, 352, 355
- hypoxia-inducible factor 1 (HIF-1) 209–210
- i**
- iberdomide 350
- i, i+4 stapling 222
- i, i+7 stapling 222
- i, i+11 stapling 222
- Ikaros 360
- immune cell migration 3, 8
- immune response 8–9
- immune system, PPIs 119
- immunoblotting 363
- immunomodulatory drugs (IMiDs) 349–351, 360
- immunosensors 18
- incident light 115, 116
- indisulam 347, 351, 352
- 2-indolecarboxylic acid 292
- indole-2-carboxylic acid 290, 292, 294
- infectious diseases 11, 18, 33, 121, 125, 126, 219, 220, 226, 230, 231, 236
- inhibition constant (K_i) 165, 269–275, 278, 281–292, 294–296, 298–299, 301, 303–304, 306–307, 376–378
- in situ PLA 107–110
- IntAct database 391, 392
- intensity-based methods 62
- intracellular signal transduction 357
- islet amyloid polypeptide (IAPP) 164, 166, 167, 169–171, 183, 185–189
- isoelectric focusing (IEF) 90
- isothermal titration calorimetry (ITC) 13, 167, 168, 174, 177, 180, 213, 246, 306, 307, 314, 375–381

j

JNJ-4355 288, 294, 299–300
 JNJ-78394355 288, 300

k

Keap1-Nrf2 PPI 49–51
 KRAS 358, 361, 363–364
 Kras-SOS1 49
 KSR (kinase suppressor of RAS)
 357–358

l

labeling biomolecules 62
 lactam bridges 222
 lactamization 222–223, 231
 large-scale PPI network mapping 13–14
 lecanemab 122
 Lennard-Jones potential 145
 Lewy bodies 11, 180
 limited proteolysis–mass spectrometry
 (LiP-MS) 93–95
 liquid chromatography–tandem mass
 spectrometry (LC-MS/MS) 75,
 79, 85, 87, 88, 91, 92, 94
 liver fibrosis, PPIs 119
 Lphn2 Lec domain 125
 lymphomagenesis 322
 lysine 83, 86, 87, 222–223, 225, 228

m

macrocyclic peptides 255
 magnetic streptavidin beads 87
 MAI-150-derived peptidomimetic
 inhibitors 377
 MAI-203 377–382
 MAI-400 378–382
 MAI-516 380–381
 major histocompatibility complex (MHC)
 8–9, 11, 119
 Markov cluster (MCL) method 394
 masked strategy 279
 mass spectrometry (MS) 13, 14, 45–46,
 69, 75–96, 116, 123, 315, 352, 362,
 363, 397
 matrix metalloproteinase 9 (MMP9) 373

MCL-1 41, 42, 229, 249, 250, 280–281,
 293, 357
 MDM2 proto-oncoprotein 343
 MDM2-p53 interaction 44, 227–228
 MEK inhibitor 357
 Menin-MLL 48–49
 mezigdomide 350
 MIM-1 281
 miR-1-NOTCH3 signaling pathway 374
 mitogen-activated protein kinase (MAPK)
 signaling 6, 129, 163, 321, 358
 molecular docking 17, 19, 30, 36, 38, 51,
 118, 304, 323, 397, 400
 molecular dynamics (MD) simulations
 15, 30, 38, 51, 70, 125, 154, 254,
 382, 397, 400, 401
 molecular glue degraders (MGDs) 131,
 347–354, 360, 361, 363
 molecular glue discovery
 methods 358–364
 modifications of E3 ligands 360
 phenotype-based screening 361–363
 target-based screening 363–364
 molecular glues (MGs) 344, 347, 348,
 360, 362, 364
 classification 347–358
 definition 347
 degraders 347–354
 design principles 347
 inhibitors 357–358
 stabilizers 354–357
 targeted protein degradation 347
 molecular interaction database (MINT)
 391, 392, 394
 molecular interactions 29, 34, 63, 65, 67,
 69–71, 115, 116, 118, 132, 304
 multimodal tags 80
 multiple sequence alignments (MSAs)
 144, 149, 150, 154
 mutagenesis 209, 306, 307, 309, 320
 mutation cluster region (MCR) 374
 Mxra8 126

n

N2a cells 190, 191, 215
 nauclefine 356, 357

NCT02 353–354
 neddylation 361
 neoplastic progression 10–11
 network-based methods 15–16, 391, 394
 neurodegeneration, antagonists of 166–168
 neurodegenerative diseases 11, 16, 33, 49, 50, 123, 124, 130, 163, 174, 180, 220, 226, 234, 236, 343
 neuronal migration 125
 neutralizing antibodies (Nab) 121, 122, 128
 non-anticoagulant heparin (NAH) 129
 N-terminal cysteine-rich domain (Cys-rich domain) 300
 nuclear magnetic resonance (NMR) 12, 30, 37–41, 66, 69, 123, 132, 140, 166, 168, 169, 171, 174, 177, 180, 181, 187, 190–192, 209, 275, 281, 291, 292, 301, 314, 316, 322–323
 NYAD-1 231, 252

O

off-target effects 36, 37, 42, 50, 227, 232, 233, 236, 280, 364, 383
 OICR12694 317–318
 oligomerization domain (OD) 373
 oligopyridylamide (OPs) and Alzheimer's disease 173–174
 antagonists of neurodegeneration 166–168
 evolution of 164–165
 HIV infection 168, 169
 targeting and reactivating mutant protein 171–173
 targeting type II diabetes 169–171
 OpenPepXL 87
 OQ foldamers
 chemical diversity 188–189
 manipulation of 186–188
 structure and discovery 181–182
 structure modulate efficacy of 188–189
 synthesis of 182–183
 type II diabetes-related aPPis of 183–186

OQs, synucleinopathies 191–194
 oral bioavailability 17, 41, 212, 213, 231, 233, 235, 256, 276, 293, 304, 316, 318
 orthosteric regulators 344
 osteoporosis 124–125, 397

P

p53-dependent apoptosis 246
 p53-MDM2 43–44
 p53-MDM2/MDMX PPI's inhibitor 208
 p53 mutations, R248W (pR248W) 172
 Pan-coronavirus fusion inhibitor 212–213
 pancreatic ductal adenocarcinoma (PDAC) 128
 parallel artificial membrane permeability assay (PAMPA) 180, 212
 parallel artificial membrane permeability assay-blood-brain barrier (PAMPA-BBB) 209–210
 PD-1/PD-L1 17, 47–48, 51, 255
 PDE3A 354–357
 peptides 44
 computer-aided design of tripeptide inhibitors 381
 MAI-150-derived peptidomimetic inhibitors 377
 MAI-203 377–379
 MAI-400 379–380
 MAI-516 380–381
 minimal Asef sequence 376
 and protein mimics 400–401
 peptidomimetics 205, 207–210, 213, 216, 377
 phenyl-piperidine derivatives 303–305
 phenylpyrazole 279
 phi29 DNA polymerase 107
 phosphoantigens (pAg) 119
 phospho-degron 363
 phosphoinositide 3-kinase (PI3K) 6, 374
 phosphoinositides 64
 photo-controlled peptide 229
 phthaloyl-protected amino acid 224
 poly-glycine linkers 149
 pomalidomide 131, 350

- PPI inhibitors 128
 - PPI stabilizers 129–130
 - proapoptotic proteins 264, 266, 281, 294
 - protein aggregation 188, 192
 - protein assemblies 18, 75
 - protein complex prediction 154, 389, 394–395, 402
 - protein degradation pathway 9–10
 - protein interaction reporter (PIR) 87
 - protein-mimetics 164–166, 168, 171, 174, 186
 - protein misfolding 64, 220, 234
 - ProteinMPNN 256
 - protein–nucleic acid interaction 63, 108
 - protein of interest (POI) 76, 92, 94, 109
 - protein–protein docking 140–148, 152
 - protein–protein interactions (PPIs) 263
 - advancing disease understanding and diagnosis 16, 17
 - affinity 13
 - antigen–antibody interactions 3–4
 - BCL-2 family antipoptotic protein inhibitors 267–300
 - B-cell lymphoma 9 (BCL9) 300–301
 - biotechnology, fostering innovations in 17, 18
 - in cellular processes 32, 33
 - cellular signal transduction 5, 6
 - chaperone–client interactions 4
 - computational methods for 38–40
 - definition of 1
 - at different scales 390
 - disease mechanisms 10–11
 - in disease pathways 32–33
 - driving target-based drug discovery 17
 - druggability issues 35
 - dynamics and flexibility of 34–35
 - enzyme–substrate interactions 3
 - gene expression regulation 6–8
 - heterogeneity of 34
 - hotspots 263
 - hot zone 263
 - immune response 8
 - kinetics, and thermodynamics
 - measurement 13
 - large-scale PPI network mapping 13, 14
 - modulators 344
 - antibodies 401
 - peptides and protein mimics 400–401
 - small molecules 397–400
 - types of 396
 - molecular glues (MGs) 344
 - network-based methods 15, 16
 - network mapping 390–394
 - principles of 30–32
 - protein complex prediction 394–395
 - protein degradation pathway 9–10
 - receptor–ligand interactions 3
 - scaffold interactions 4
 - sequence-based methods 14–15
 - structural complexities of 33–34
 - structural properties of 2–3
 - structure-based methods 15
 - structure determination 12
 - types of 32
 - proteins of interest (POIs) 347, 363
 - proteolysis targeting chimeras (PROTACs) 84, 130, 131, 230, 246, 347
 - proteolytic stability, enhanced 225–226
 - proteomic analysis 17, 363
 - proteomics-based screening 362–363
 - proximity-induced reactions 106
 - proximity labeling (PL) 79, 81–84, 95, 363
 - proximity ligation assay (PLA)
 - applications of 108–109
 - implementations of 106–107
- q**
- quantitative proteomics 361–363
 - quantitative real-time PCR (qPCR)
 - analysis 305
 - quantitative structure–activity relationship (QSAR) models 38
 - quantitative XL-MS 88
 - quercetin 302, 303

r

rapamycin 357
 RAS-MAPK 129
 RBM39 351, 361
 (R)-CR8 351–354
 reactivating mutant protein 171–173
 receptor activator of nuclear factor- κ B
 ligand (RANKL) 124–125
 receptor–ligand interactions 3, 5
 recombinant protein expressions
 232
 respiratory syncytial virus (RSV) 94,
 230, 252
 RFdiffusion 39, 256
 Rho guanine nucleotide exchange factor
 4 (Asef) 373
 rolling circle amplification (RCA) 107
 Roscovitine 46

s

S55746 279, 292
 S63845 41, 277, 291–292
 S64315 41, 291, 292
 sampling 15, 91, 93, 141–145, 148, 153,
 194
 SARS-CoV-2 infection 11, 16, 252
 scaffold interactions 4
 scalable chemical profiling 352, 361, 362
 scoring function
 deep learning-based 146–147
 traditional 145–146
 seal limb 349
 seed-catalyzed aggregation 167, 168, 192
 selective Bcl-2/Bcl-xl inhibitors 268–280
 selective Mcl-1 inhibitors 280–292
 sequence-based methods 14–15, 394,
 395
 signal transduction 3, 5–6, 32–34, 51,
 105, 108, 139, 163, 219, 263, 357,
 391
 singlet oxygen generators (SOG) 84
 size exclusion chromatography (SEC)
 87, 88
 SLFN12 354–357

small molecule inhibitors 30, 34, 35, 41,
 42, 47, 50, 120, 219, 220, 225, 234,
 235, 243, 263–323, 358, 381–383,
 397
 small-molecule PPI modulators
 344–346, 396, 397
 small molecules 396, 398
 SNAP-25A fragment 253
 Sonrotoclax 276–278
 spatial replacement strategy 275
 split APEX (sAPEX) 83
 stabilized alpha-helix of Bcl-2 domains
 (SAHBs) 42
 stapled peptides 219
 α -helical structures 221
 azide–alkyne cycloaddition 223
 biological barriers 232, 233
 C–H activation 224
 Cys–Cys stapling approach 224
 delivery technologies 235, 236
 in drug discovery 220
 early development of 220, 221
 lactamization 222, 223
 manufacturing and cost 232
 mechanism of 221, 222
 off-target effects 233
 resistance mechanisms 233, 234
 therapeutic modalities 235
 tyrosine stapling 224–225
 staple placement 222
 stapling chemistry 222
 strain-promoted azide–alkyne
 cycloaddition (SPAAC) 62
Streptomyces 357
 STRING database 391
 strong cation exchange (SCX) 87
 structural biology 4, 12, 17, 30, 37, 39,
 51, 66, 84, 264, 275, 351, 364
 structural optimization 48, 278, 291,
 310, 316, 317, 323, 355
 structure–activity relationship (SAR) 30,
 38, 43, 207, 281, 306, 350, 377
 structure-based drug design (SBDD) 29,
 36–37, 45, 276, 281, 294
 structure-based methods 15, 394

- sulfonamides 44, 275, 276, 304, 351, 361
- sulfonyl- γ -AApeptides
 - β -catenin/B-cell lymphoma 206–208
 - HIF-1 α PPI's inhibitor 209–210
 - p53-MDM2/MDMX PPI's inhibitor 208
- surface plasmon resonance (SPR)
 - advantages of 116–117, 131–132
 - angle of incidence 115
 - limitations of 131, 132
 - in PPI characterization 117–131
 - principle of 115–116
- SW480 cells 207, 302, 303, 306, 379, 381
- synaptotagmin-2 253
- synucleinopathies 191–194
- t**
 - tag-specific detection 108
 - tandem mass tag (TMT) 90
 - targeted protein degradation (TPD) 130–131, 172, 347, 360, 402
 - targeting BCL-2 family proteins 228–229, 290
 - targeting mutant protein 171–173
 - targeting type II diabetes 169–171
 - T-cell antigen recognition and activation 8–9
 - T-cell receptor (TCR) 8, 119, 321
 - Tedious Synthetic Route 165, 166
 - template-based docking 140, 147–148
 - thalidomide 349, 350
 - thermal proximity co-aggregation (TPCA) 90–93
 - thiol-ene reaction 224
 - thiol-ene stapling 224, 228
 - thionyl chloride (SOCl₂) 174, 183
 - TMX-2164 310–315
 - traditional scoring functions 145, 146
 - traditional search algorithms 142–144
 - tricyclic indole-diazabenzodiazepinone 293
 - triethylamine 166, 174
 - triggering receptor expressed on myeloid cells 2 (TREM2) 123
 - TTX-810 281
 - tumor suppressor p53 10, 343
 - TW-37 281
 - 2-dimensional fragment-assisted structure-based technique (2D-FAST) 176, 181
 - type II diabetes-related aPPIs 183–186
 - tyrosine stapling 224–225
- u**
 - ubiquitination 9, 84, 130, 131, 322, 343, 348, 352–354, 361, 363, 391
 - UMI-77 281
 - undruggable PPIs 226–227, 236
 - UV irradiation 81
- v**
 - validation of PPI interface 123–126
 - venetoclax 17, 41, 276, 278, 292, 344
 - virtual screening 17, 36, 39, 291, 317, 323, 382, 397
 - virus–host recognition 120
- w**
 - WEHI-539 42, 280
 - WK500B 316–317
 - Wnt signaling pathway 229, 300, 307
 - Wnt target gene expression 304, 306
- x**
 - X-linked inhibitor of apoptosis (XIAP) 17, 44, 45
 - XlinkX 87
 - X-ray crystallography 12, 30, 37, 38, 43, 66, 123, 132, 140, 154, 164, 165, 294, 308, 316, 317, 322, 323
 - XY4-7C 213
- y**
 - yeast two-hybrid (Y2H) screening 13, 116, 390, 391